Investigator Clinical Neuroscience Solutions, Inc. 5200 Belfort Road, Suite 420, Jacksonville, FL 32256 2003 - Present
2003-Present Principal Investigator on over 200 phase II – IV clinical
trials in children, adults, and geriatrics. Diagnoses include: fibromyalgia, addictions, hypertension, ADHD, Alzheimer’s disease, pain, bipolar disorders, dementia, gout, depressive disorders, migraine, sexual function (male and female), diabetes, diabetic neuropathy, asthma, general anxiety disorder, autism, insomnia, obesity and eating disorders, mild cognitive impairment, opioid induced constipation, schizophrenia, smoking cessation, and menopausal symptoms.
Internal Medicine and Neurology Internship, Emory
University School of Medicine, Atlanta GA
Psychiatry Residency, Emory University School of Medicine, Atlanta, GA
Chief Resident, Department of Psychiatry, Grady Memorial Hospital, Atlanta, GA
1992 – 1996 Consultant, Gwinnett/Rockdale/Newton Recover Center 1996 – 2000 Medical Director, Gwinnett/Rockdale/Newton Recovery
2001-2006 Director of Psychiatric Services, Duval County Pretrial Detention Center 2001- Present Private Practice, Jacksonville, FL
B.S., Birmingham Southern College Department of Psychology Birmingham, AL
M.D., University of Alabama School of Medicine
CNS Healthcare Jacksonville - 5200 Belfort Road, Suite 420, Jacksonville, Florida 32256
Tel: (904) 281-5757 Fax: (904) 281-5758 Mobile (904) 654-6451
Florida: No. ME 81135 Georgia: No. 032593
Drug Enforcement Administration: BJ7100833 (Florida) & BJ3162601 (Georgia) American Board of Psychiatry and Neurology
Industry contracts include: Abbott, Addrenex Pharma, Alkermes, Allergan, Allon Therapeutics, Array, AstraZeneca, Avera, Bristol-Myers Squibb, Boehringer Ingelheim, Cephalon, DOV, Eli Lilly, Epix Pharmaceuticals, Euthymics, Forest, Furiex, GlaxoSmithKline, Indevus, Johnson & Johnson, Labopharm, Lundbeck, Merck, McNeil, Myriad, Neurocrine, New River Pharmaceuticals, Novartis, Ono Pharma USA, Organon, Otsuka, Pfizer, Purdue, Rexhan, Sanofi, Sepracor, Shionogi, Shire, Solvay, Somaxon, Sunovion, Supernus, Takeda, Targacept, TransTech, Vanda and Wyeth.
McCallum, D.M., McCallum, R., Gurwitch, R.H., & Joyce, J.M. (1986). Assessing Perceptions of Dental Health Behaviors. Clinical Preventative Dentistry, 8, 27-30. Hughes, T.A., Moore, M.A, Joyce, J.M., Go, R.C.P, Segrest, J.P. & Blackwell, T. (1992).Sexual Differences in Lipoprotein Composition in Dyslipidemic Hypertension with Premature Atherosclerosis: Deficiency of HDL-l and HDL-M “A-I Alone” Particle. Journal of Laboratory and Clinical Medicine, 119(1). Weisler, R., Joyce, J.M, McGill, L., Lazarus, A., Szamosi, J., Eriksson, H. (2009). Extended Release Quetiapine Fumarate Monotherapy for Major Depressive Disorder: Results of a Double-Blind, Randomized, Placebo-Controlled Study. CNS Spectr. 2009; 14(6):299-313. El-Khalili N., Joyce M., Atkinson S., Buynak R. J., Datto C., Lindgren P., Eriksson H., Extended –Release Quetiapine Fumarate (Quetiapine XR) as Adjunctive Therapy in Major Depressive Disorder (MDD) in Patients with an Inadequate Response to Ongoing Antidepressant Treatment: A Multicentre, Randomized, Double-Blind, Placebo Controlled Study. International Journal of Neuropsychopharmacology, Vol 23:1-16, February 2010.
Joyce, M., Khan, A., Atkinson, S., Eggens, I., Baldytcheva, I., Brecher, M., (2007). Efficacy and Safety of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients with Generalized Anxiety Disorder (GAD). American Psychiatric Association Convention. Khan, A., Joyce, M., Atkinson, S., Eggens, I., Baldytcheva, I., Brecher,
CNS Healthcare Jacksonville - 5200 Belfort Road, Suite 420, Jacksonville, Florida 32256
Tel: (904) 281-5757 Fax: (904) 281-5758 Mobile (904) 654-6451
M. (2007). Efficacy and Safety of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients with Generalized Anxiety Disorder (GAD). Anxiety Disorders Association of America, 28th Annual Conference. El-Khalili, N., Joyce, M., Atkinson, S., Buynak, R., Datto, C., Lindgren, P., Eriksson, H., Brecher, M., (2007). Adjunctive Extended Release Quetiapine Fumarate (Quetiapine XR) in Patients with Major Depressive Disorder and Inadequate Antidepressant Response. American Psychiatric Association Convention. Weisler, R., Joyce, M., McGill, L., Lazarus, A., Schollin, M., Brecher, M., (2007). Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy for Major Depressive Disorder (MDD): A Double-Blind Placebo Controlled Study. Hughes, T.A., Moore, M.A., Joyce, J.M., Go, R.C.P, Segrest, J.P., & Blackwell, T. (1998). Family with Hypertiglyceridemia and Premature Atherosclerosis: “Light ApoA-1” Deficiency. Atherosclerosis, 8, 578a.
CNS Healthcare Jacksonville - 5200 Belfort Road, Suite 420, Jacksonville, Florida 32256
Tel: (904) 281-5757 Fax: (904) 281-5758 Mobile (904) 654-6451
FEDERAZIONE SCACCHISTICA ITALIANA REGOLAMENTO FEDERALE ANTIDOPING (in attesa di approvazione da parte del CONI) Testo approvato dal Consiglio Federale FSI del 22-23 settembre 2001 con recepimento del testo del "Regolamento dell'attività antidoping" approvato dal Consiglio Nazionale del CONI con provvedimento n. 1187 del 5/6/2001 Art. 1 - Definizione del doping
Publikationen - Auswahl der letzten 5 Jahre Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, Gschwantler M, Brunner H, Wenisch C, Bischof M, Strasser M, Datz C, Vogel W, Löschenberger K, Steindl-Munda P; Gastroenterology. 2010 Feb;138(2):503-12,